Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 8—August 2025

Dispatch

Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016–2023

Anna D. BakerComments to Author , Jeremy A.W. Gold, Kaitlin Forsberg, Sophie Jones, and Meghan M. Lyman
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 2

Patients with Candida auris screening cases with progression to clinical case status, by body site of clinical case detection, United States, 2016–2023*

Characteristic All, N = 1,458 Blood, n = 584 Urine, n = 391 Respiratory, n = 233 Wound, n = 168 Other, n = 82† p value‡
Median age at collection of screening case specimen, y (IQR), n = 1,238
67 (59–76)
68 (60–76)
68 (58–77)
68 (60–77)
67 (61–75)
64 (50–71)
0.023
Age group at collection of screening case specimen, y, n = 1,238 0.027
<45 118 42 (35.6) 40 (33.9) 8 (6.8) 15 (12.7) 13 (11.0)
45–54 105 35 (33.3) 27 (25.7) 21 (20.0) 11 (10.5) 11 (10.5)
55–64 279 106 (38.0) 69 (24.7) 55 (19.7) 38 (13.6) 11 (3.9)
65–74 368 134 (36.4) 97 (26.4) 68 (18.5) 48 (13.0) 21 (5.7)
75–84 274 106 (38.7) 83 (30.3) 43 (15.7) 31 (11.3) 11 (4.0)
>85
94
33 (35.1)
26 (27.7)
22 (23.4)
12 (12.8)
1 (1.1)

Sex, n = 1,183 <0.001
M 671 215 (32.0) 216 (32.2) 124 (18.5) 76 (11.3) 40 (6.0)
F
512
218 (42.6)
110 (21.5)
84 (16.4)
73 (14.3)
27 (5.3)

Antimicrobial Resistance Laboratory Network region of the facility of specimen collection for clinical case§ <0.001
West 898 306 (34.1) 252 (28.1) 173 (19.3) 124 (13.8) 43 (4.8)
Midwest 96 24 (25.0) 36 (37.5) 22 (22.9) 8 (8.3) 6 (6.3)
Southeast 56 33 (58.9) 10 (17.9) 7 (12.5) 3 (5.4) 3 (5.4)
Northeast 302 177 (58.6) 68 (22.5) 25 (8.3) 20 (6.6) 12 (4.0)
Mid-Atlantic 64 37 (57.8) 11 (17.2) 3 (4.7) 4 (6.3) 9 (14.1)
Mountain 42 7 (16.7) 14 (33.3) 3 (7.1) 9 (21.4) 9 (21.4)
Central¶
0
0 (NA)
0 (NA)
0 (NA)
0 (NA)
0 (NA)

No. days from collection date of first positive screening to first clinical case specimen# 0.001
Median (IQR) 46 (19–108) 58 (22–130) 44 (20–120) 33 (17–74) 44 (17–91) 28 (14–77)
Minimum–maximum 1–1,597 1–1,309 1–1,597 1–1,240 1–666 1–745

*Values are no. (%) except as indicated. IQR, interquartile range. †Other specimen type included device (n = 14), fluid/drainage (n = 5), intraabdominal (n = 2), other (n = 60), and unknown (n = 1). ‡p values were calculated using χ2 tests (categorical variables) or Kruskal-Wallis rank-sum test (continuous variables) to compare features of interest by body site. §https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/domestic.html. Data from 2023 were unavailable from one state in the Central region. ¶Row excluded from p value calculations because no screening-to-clinical cases were reported in the Central region. #Data missing for 1 patient with a clinical case involving a wound.

Main Article

Page created: June 16, 2025
Page updated: July 10, 2025
Page reviewed: July 10, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external